Eric Lefkofsky's guest appearances

Eric Lefkofsky

Washington Post Live

Conversations with Mike Milken

The MATTER Health Podcast

Steve Ballmer

Elaine Chao

Jennifer Doudna

Alex Gorsky

David Rubenstein

Kristalina Georgieva

Allison Arwady

Barbara Humpton

David Malpass

Ed Bastian

Kurt Newman

Al Kelly

Rick Scott

Francis Collins

Ray Dalio

OwlTail

Siddhartha Mukherjee

Washington Post health policy reporter Yasmeen Abutaleb speaks with Pulitzer Prize-winning oncologist Siddhartha Mukherjee and Tempus Labs founder Eric Lefkofsky about the latest developments in precision medicine and the promise for the future of cancer treatment.

Siddhartha Mukherjee and Eric Lefkofsky discuss precision medicine for cancer treatment

Tempus

Eric Lefkofsky is one of Chicago's most successful technology entrepreneurs. His entrepreneurial ventures include Groupon, Echo Global Logistics, Lightbank and, most recently, Tempus.As the founder and CEO of Tempus, Eric has led the company — which uses machine learning and genomic sequencing to better understand cancer tumors — to become one of Chicago's most valuable technology startups. Tempus raised $300 million last year, bringing their total financing to more than $1 billion and their valuation to $8.1 billion.The most recent infusion of capital has allowed Tempus to expand beyond oncology to additional areas, including mental health, cardiology, diabetes and infectious disease — including COVID-19. Last November, Tempus announced a collaboration with the Yale School of Public Health to develop an at-home, saliva-based, COVID-19 diagnostic test. In a conversation moderated by Paragon Biosciences Founder, Chairman and CEO Jeff Aronin, Eric discuss his career-long entrepreneurial journey, lessons he’s learned along the way and his vision for the future of Tempus.The Tales from the Trenches series invites seasoned healthcare entrepreneurs to the MATTER stage to share their journeys — from how they got started to what they’re trying to accomplish and what they’ve learned along the way. Tales from the Trenches is sponsored by Paragon Biosciences.Learn more about MATTER events here.

Eric Lefkofsky is one of Chicago's most successful technology entrepreneurs. His entrepreneurial ventures include Groupon, Echo Global Logistics, Lightbank and, most recently, Tempus. As the founder and CEO of <a href="https://www.tempus.com/" rel="nofollow" target="_blank">Tempus</a>, Eric has led the company — which uses machine learning and genomic sequencing to better understand cancer tumors — to become one of Chicago's most valuable technology startups. Tempus raised $300 million last year, bringing their total financing to more than $1 billion and their valuation to $8.1 billion. The most recent infusion of capital has allowed Tempus to expand beyond oncology to additional areas, including mental health, cardiology, diabetes and infectious disease — including COVID-19. Last November, Tempus announced a collaboration with the Yale School of Public Health to develop an at-home, saliva-based, COVID-19 diagnostic test. In a conversation moderated by <a href="https://paragonbiosci.com/" rel="nofollow" target="_blank">Paragon Biosciences</a> Founder, Chairman and CEO Jeff Aronin, Eric discuss his career-long entrepreneurial journey, lessons he’s learned along the way and his vision for the future of Tempus. The Tales from the Trenches series invites seasoned healthcare entrepreneurs to the MATTER stage to share their journeys — from how they got started to what they’re trying to accomplish and what they’ve learned along the way. Tales from the Trenches is sponsored by Paragon Biosciences. <a href="https://matter.health/events?utm_source=buzzsprout&amp;utm_medium=podcast1&amp;utm_campaign=event_page" rel="nofollow" target="_blank">Learn more about MATTER events here</a>.

Tales from the Trenches™ with Eric Lefkofsky, CEO & Founder, Tempus

Eric Lefkofsky, Founder and CEO, Tempus“Today, if somebody’s positive for COVID-19, it still doesn't tell you what's likely to happen next. And what we're trying to do by combining clinical and molecular data is really be able to predict what's likely to happen to them next.”When Groupon founder Eric Lefkofsky’s wife was diagnosed with cancer, he found a lack of data maddening. Outside of her hospital, it was the 21st century, but once he passed through the doors he felt he was being ushered two or three decades into the past.He launched Tempus to change that. The company analyzes vast pools of genetic data to find and develop therapeutics for conditions ranging from cancers to major depressive disorder. He’s especially frustrated at the lack of progress in the current crisis. “We now have in this country over 400,000 patients who have tested positive for COVID-19,” he tells Mike. “Where is that data? Why don’t we have that data in one central place?”For Lefkofsky, the promise of personalized medicine means finding and developing the right medicine for the right patient at the right time. Today, any of us may be the next patient, and the clock is ticking.

Eric Lefkofsky, Founder and CEO, Tempus“Today, if somebody’s positive for COVID-19, it still doesn't tell you what's likely to happen next. And what we're trying to do by combining clinical and molecular data is really be able to predict what's likely to happen to them next.”When Groupon founder Eric Lefkofsky’s wife was diagnosed with cancer, he found a lack of data maddening. Outside of her hospital, it was the 21st century, but once he passed through the doors he felt he was being ushered two or three decades into the past.He launched Tempus to change that. The company analyzes vast pools of genetic data to find and develop therapeutics for conditions ranging from cancers to major depressive disorder. He’s especially frustrated at the lack of progress in the current crisis. “We now have in this country over 400,000 patients who have tested positive for COVID-19,” he tells Mike. “Where is that data? Why don’t we have that data in one central place?”For Lefkofsky, the promise of personalized medicine means finding and developing the right medicine for the right patient at the right time. Today, any of us may be the next patient, and the clock is ticking.

Ep. 11: Impatient, with Tempus/Groupon’s Eric Lefkofsky